Minigastrin I (human)

Minigastrin I (human) is a short-chain neuropeptide with the molecular formula C₇₄H₉₉N₁₅O₂₆S and molecular weight 1645.66 g/mol. As a human-specific analog of gastrin, it is widely used to study gastric acid regulation, CCK₂ receptor signaling, and preclinical drug development for acid-related disorders.

Send Email

Download

TECHNICAL SPECIFICATIONS

Item	Specification
Product Name	Minigastrin I (human)
CAS NO.	\
Appearance	White to off-white lyophilized powder
Molecular Formula	C₇₄H₉₉N₁₅O₂₆S
Molecular Weight	1645.66 g/mol
Purity (RP-HPLC)	≥ 98.0%
Solubility	Freely soluble in deionized water (pH 4.0–7.0) or 0.1 M acetic acid; partially soluble in DMSO (≤2 mg/mL) to avoid precipitation.
Endotoxin	< 1.0 EU/mg
Biological Activity	Human-specific minigastrin analog with high affinity for the cholecystokinin-2 (CCK₂) receptor (Ki: 0.2–2 nM). Stimulates gastric acid secretion, gastrin release, and proliferation of gastric mucosal cells. Shorter length enhances stability compared to full-length gastrin, ideal for rapid signaling studies.
Storage Conditions	Lyophilized powder: Store at -20°C in a tightly sealed, light-protected container; avoid moisture and repeated freeze-thaw cycles.
Stock Location	Stock in USA
MOQ	1g

1.MECHANISM OF ACTION

CCK₂ Receptor Activation: Binds to the cholecystokinin-2 (CCK₂) receptor (human, Ki: 0.2–2 nM), triggering Gq/11 protein-coupled signaling cascades.

Gastric Acid Secretion: Stimulates enterochromaffin-like (ECL) cells in the stomach to release histamine, which induces gastrin secretion from G cells, ultimately increasing gastric acid production.

Mucosal Growth: Promotes proliferation of gastric mucosal cells via CCK₂ receptor-mediated MAPK/ERK pathway activation, supporting tissue repair and regeneration.

2.PRODUCT INDICATIONS

Gastrointestinal Research: Studying gastric acid regulation, peptic ulcer disease, and gastroesophageal reflux disorder (GERD) in human-relevant models.

Pharmacology Studies: Evaluating CCK₂ receptor antagonists (e.g., proton pump inhibitors, H₂ blockers) and agonists for acid suppression or mucosal protection.

Preclinical Drug Development: Testing the efficacy and safety of anti-ulcer drugs, gastric stimulants, or CCK₂-targeted therapies in human-derived cell lines or organoids.

3.CLINICAL EFFICACY OF PRODUCT

Preclinical Validation:

Increases gastric acid output by 50–70% in human gastric gland cultures (ED₅₀: 0.5 nM).

Stimulates gastrin release from human G cells by 4–6x (concentration: 1 nM).

Promotes gastric mucosal cell proliferation (2–3x increase in BrdU incorporation) in human organoid models.

Therapeutic Relevance: CCK₂ receptor antagonists derived from Minigastrin I (human) are in clinical trials for acid-related disorders, with this peptide serving as a key reference standard.

4.DELIVERY & SHIPPING

We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods
Main Method: International Air Freight

We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.